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Summary
The basic principle of RNA interference, a possible new therapeutic tool, involves de-
struction of messenger RNA upon interaction with homologous double-stranded RNA
present in the cell cytoplasm. Studies have shown that both viral and non-viral small in-
terfering RNA delivery methods and delivery of chemically synthesized small interfering
RNAs to the cell can provide selective gene suppression through this mechanism, both in
vitro and in vivo. Before becoming a functional therapeutic tool, there are a number of
problems concerning RNA interference that should be solved. Major problems involve off-
-target effects, insertional mutagenesis and malignant transformation, as well as problems
of delivery methods and reduction of toxicity.
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Introduction
Using genomic information as a target for drug
therapy has always been and still is a great challenge to
pharmaceutical companies. The main problem, however,
is how to determine the gene products functionally in-
volved in the pathology of a certain disease and how
many genes are involved. Application of RNA interfer-
ence (RNAi) in solving this problem started after the
discovery of an evolutionary conserved mechanism of
posttranscriptional gene silencing by double-stranded
RNA (dsRNA) in a range of eukaryotic organisms: plants,
Neurospora crassa, Drosophila melanogaster, Caenorhabditis
elegans, and mammals (1).
Mechanism of RNAi
In mammalian cells, naturally occurring posttran-
scriptional gene silencing is mainly mediated by micro-
RNA (miRNA). Double-stranded miRNAs are processed
into short dsRNAs through a cascade of biochemical
events involving the cytoplasmic ribonuclease III (RNase
III)-like protein Dicer and the RNA-induced silencing
complex (RISC). Dicer enables the formation of small
RNA duplexes, 19–25 base pairs long, with characteristic
3’-dinucleotide overhangs, a 5’-monophosphate and a 3’-
-hydroxyl group, but requires the cooperation of dsRNA
binding proteins to complete its function. Homologues
of this protein can be found in Saccharomyces pombe, C.
elegans, D. melanogaster, plants, and mammals. A product
of Dicer, small dsRNA, consists of two strands: the guide
or antisense strand, which is complementary to the tar-
get sequence and will trigger its recognition by RISC,
and the passenger or sense strand, which provides sta-
bility to dsRNA. To choose which of the two strands will
be given the function of the guide strand, the dsRNA
product of Dicer cleavage is handed off to Argonaute 2
protein (Ago2), a Dicer-interacting protein and part of
RISC, which then cleaves the passenger strand, dissoci-
ating it from the RISC. In the same way, a small interfer-
ing RNA (siRNA) duplex of exogenous origin is incor-
porated into the RISC, whereupon an ATP-dependent
helicase unwinds the duplex, enabling one of the strands
to independently recognize messenger RNAs (mRNAs).
RISC carries out the final gene silencing step. Ago2 is its
catalytic or slicer component. Two different domains in
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Ago2, Piwi domain (named after the Piwi protein in D.
melanogaster) and Piwi-Argonaute-Zwille (PAZ) domain,
bind the 5’ and 3’ ends of the guide strand. The 5’ end
bound to the Piwi domain determines target recognition
and the site of cleavage. Nucleotides 2–8 of the guide
strand, known as the seed sequence, initiate pairing
with the target mRNA. Ago2 cleaves the mRNA be-
tween the nucleotides complementary to bases 10–11 of
the guide strand. The generated 5’ and 3’ mRNA frag-
ments are then degraded by different exonucleases (Fig.
1). The 3’ end of the guide strand bound to the PAZ do-
main of Ago2 plays no essential role in target recogni-
tion but provides a helical geometry required for the
catalytic step. The presence of mismatches in the 3’ half
beyond nucleotide 11 slows down the rate of mRNA
cleavage (1–5).
Naturally Occurring miRNA
Naturally occurring miRNAs are synthesized in the
nucleus from miRNA genes, which are transcribed by
RNA polymerase II into long RNA, known as primary
miRNA (pri-miRNA). Pri-miRNA contains an 80-nucleo-
tide long hairpin flanked by single-stranded RNA se-
quences of a few hundred nucleotides. Pri-miRNAs are
recognized by a complex formed by the DiGeorge syn-
drome critical region 8 (DGCR8) protein and Drosha in
the nucleus. DGCR8 is a dsRNA-binding protein that
helps identify the cleavage site, whereas Drosha is a
RNase III that cleaves the pri-miRNA to generate a 70-
-nucleotide long hairpin RNA known as miRNA precur-
sor. Drosha products have typically 2 or 3 nucleotide 3’
overhangs that facilitate the transport of miRNA precur-
sors to the cytoplasm where they are further processed
by Dicer.
When planning therapeutic RNAi experiments, sev-
eral features of the nuclear processing of miRNA have
to be taken into consideration. One of the prospects in
RNA therapeutics design is to establish specific struc-
tural requirements that imitate endogenous pri-miRNA
in order to ensure their recognition by DGCR8 protein
and processing by Drosha. Inadequate design and there-
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Fig. 1. RNAi can be achieved with any long dsRNA of endogenous (miRNA) or exogenous origin (shRNA). Long dsRNAs are pro-
cessed into short dsRNAs through the activity of Dicer, an endoribonuclease in the RNase III family. Small RNA duplexes 19–25
base pairs long, as well as exogenously introduced siRNAs, are further incorporated into the RNA-induced silencing complex
(RISC), whereupon an ATP-dependent helicase unwinds the duplex. Domains in Argonaute 2 protein (Ago2), Piwi protein and
Piwi-Argonaute-Zwille (PAZ) domain bind the 5’ and 3’ ends of the guide strand and enable binding to the target mRNA and its
cleavage. The 5’ and 3’ mRNA fragments generated are then degraded by different exonucleases
by inefficient nuclear processing of a hairpin would end
in nuclear accumulation of non-processed transcripts
and ineffective silencing of the target (2,6,7).
Antisense Molecules vs. RNAi Technology
The first major experiments in RNA gene therapy
were performed with single-stranded antisense mole-
cules (oligodeoxynucleotides). Although the final result,
the degradation of target mRNA, is identical, the mech-
anism of gene silencing by antisense molecules and
siRNAs or short hairpin RNAs (shRNAs) in mammalian
cells is different (8). Antisense molecules are synthetic
single-stranded oligonucleotides that are usually com-
posed of DNA sequences capable of Watson-Crick base
pairing to a complementary sequence in the target mRNA.
Translation of target mRNA into protein is either blocked
by steric interruption of binding to the ribosome, or by
cleavage of the mRNA through the activity of endonu-
cleases RNase H or RNase L (9,10). Parallel delivery of
antisense oligodeoxynucleotides and siRNA, both tar-
geted to the coding region of a gene, showed greater
stability as well as efficiency in the case of siRNA.
Until 2009, however, only a few of the antisense
oligonucleotides entered clinical trials as therapeutic op-
portunities. One of them, ISIS 301012 (mipomersen), a
human specific apolipoprotein B-100 (apoB-100) antisense
inhibitor, is currently in Phase 3 clinical development for
treating hypercholesteremia. ApoB-100 is a protein com-
ponent of atherogenic lipids and triglycerides, including
LDL cholesterol, synthesized and packaged into lipopro-
tein particles in the liver of different species. LDL choles-
terol is one of the risk factors of coronary heart disease
and atherosclerosis and therefore a good target for
antisense inhibition. Administration of ISIS 301012 pro-
duced remarkable reductions in mRNA and liver pro-
teins, resulting in a decrease of serum apoB-100, LDL
cholesterol and total cholesterol. Delivery was tested on
multiple animal species, including mice, hamsters, rabbits
and monkeys, before antisense inhibitor was applied in
treating human hypercholesteremia (11).
To date, the only antisense oligonucleotide that has
been approved by the U.S. Food and Drug Administra-
tion (FDA) for use in therapeutics is Vitravene (fomivir-
sen sodium intravitreal injectable), designed to treat
cytomegalovirus (CMV) infections in CMV retinitis, the
most common opportunistic infections in patients with
acquired immunodeficiency syndrome (AIDS). Vitra-
vene is a 21-base synthetic phosphorothioate oligonu-
cleotide designed to be complementary to mRNA that
encodes CMV proteins for the major immediate-early re-
gion (IE2). Binding to this location leads to specific inhi-
bition of gene expression of essential viral proteins, but
only in the eye into which it is injected. Vitravene is not
designed for treating CMV anywhere else in the body
(12,13).
RNAi with siRNA and shRNA
Specific and effective silencing of genes by RNAi
can be achieved in two ways: by using siRNA, up to 25
nucleotides long, and by using shRNA. However, one
has to be cautious because unlike in C. elegans and D.
melanogaster, where gene silencing can be achieved using
long (>500 bp) dsRNA without any adverse effect, dsRNA
of >30 bp can trigger a g-interferon response in mamma-
lian systems. The interferon response, which is other-
wise an important defence mechanism against viral in-
fection, can result in global repression of translation.
Some other problems, regardless of immunological
responses and specificity, need to be resolved when
using RNAi in vivo. For example, in contrast to C. ele-
gans, where RNAi effects are stable, long lasting, and are
passed on to the offspring, gene silencing by transfected
siRNA duplexes in mammalian cells is temporary. Gene
silencing is dependent on the number of siRNA mole-
cules introduced into cells and the number of duplexes
per cell decreases as cells divide. For this reason, the si-
lencing of targeted genes by synthetic siRNA is usually
limited to 2 weeks, or even only 3–7 days in rapidly di-
viding cells. In most diseases, especially cancer, which is
characterized by fast and uncontrollable division of cells,
persistent suppression of the targeted gene would be
necessary to prevent disease progression. The use of
siRNA would therefore require repeated transfection of
cells with siRNA. To avoid this problem, a vector-based
system for the introduction and stable expression of
siRNA in target cells has been developed. These DNA
vectors contain an RNA polymerase III promoter and a
transcription termination site. After their transcription,
by cellular machinery, the RNAs fold in the shape of
shRNAs with a stem-loop structure, which are later
cleaved by Dicer to produce 19–25 nucleotide siRNAs.
As the DNA template for shRNA does not have the
structural characteristics of pri-miRNA, it does not un-
dergo Drosha processing in the nucleus. Once they are
processed by Dicer and incorporated into RISC in the
cytoplasm, 19–25 nucleotide siRNAs lead to target cleav-
age, the target being mRNA (Fig. 1) (10,14,15). As
siRNAs have become more widely used, the basic struc-
ture of effective siRNAs has been defined as a duplex
with a 2-nucleotide overhang on the 3’ ends in compli-
ance with miRNA processing. It has also become evi-
dent that the effectiveness of siRNA silencing is se-
quence specific.
Design, Stability and Delivery of siRNA
Using a bioinformatics programme, the potential
target for RNAi should be identified on the basis of its
role in the disease process. Another prerequisite is that
its suppression should not be harmful. Once a specific
gene has been selected, a targeting sequence has to be
identified to achieve effective silencing with minimal
off-target effects. First, it is important to select a se-
quence that is unique to our targeted gene by using the
Basic Local Alignment Search Tool (BLAST). Genes that
contain significant matches with the selected region
should be monitored to verify that they are not being si-
lenced. Another tip is to select sequences displaying a
thermodynamic profile that favours incorporation of the
guide strand into the RISC (16,17). Most researchers
screen a minimum of 4 or 5 different target sequences
for each gene before choosing the most effective one.
However, even sequences that display efficacy in screen-
ing experiments might lead to unexpected toxicity in
vivo, suggesting that more than one therapeutic con-
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struct should be selected for therapeutic trials in animal
models. That is why two or three different sequences for
siRNA target site are synthesized; the most specific and
effective siRNA sequence must be validated by measur-
ing the levels of the target mRNA or protein in vitro
(2,18).
siRNA should be generally designed in such a way
as to be fully complementary to its target mRNA. First,
a few parameters affecting the siRNA or shRNA func-
tion have to be examined in the design process. The
guanine-cytosine (GC) content of a siRNA duplex is a
parameter that might correlate with siRNA functionality.
Too high GC content may slow down duplex unwinding
and might be associated with a prohibitive secondary
structure of the target mRNA. Guanine-rich RNA se-
quences can also form Hoogsteen-paired quartets of G
residues, or the so-called ’tetrads’, which cause difficul-
ties during RNA synthesis and purification. Too low GC
content, on the other hand, may reduce the efficiency of
target mRNA recognition and hybridization. Analysis of
the biochemistry and mechanisms of RNAi revealed that
base pair mismatches introduced at the 5’ end of siRNA
improved gene silencing. Also, duplex end asymmetry,
in the form of differences in adenine-uracil (AU) content
between the three terminal nucleotides of the 3’ and 5’
ends, rather than duplex properties, correlated most
strongly and highly significantly (p=0.005) with siRNA
functionality (16,17).
Although siRNA molecules appear to be more resis-
tant to nuclease degradation than antisense molecules,
some serum nucleases can degrade siRNAs. As a result,
many research groups have investigated the use of che-
mical modifications that improve stability and protect
against nuclease degradation. Several groups showed
that boranophosphate-modified siRNAs were 10 times
more nuclease resistant than unmodified siRNAs (19).
Along with successful siRNA design, efficient delivery is
another essential characteristic of gene silencing in mam-
malian systems. Chemically synthesized siRNAs, viral
or non-viral vectors expressing shRNA, can be delivered
locally or systematically to silence the target gene in
vivo. Chemical modifying of siRNAs renders them resis-
tant to RNAse digestion and extends their half-life.
Modifications reported in the literature include capping
the 5’ end, modifying the ribose sugars or substituting
phosphorothioates, 2’-O-methyl-RNA nucleotides at the
5’ end and four methylated monomers at the 3’ end.
Complexing siRNA or shRNA expressing plasmids with
cationic polymers or peptides or incorporating siRNAs
into liposomes and nanoparticles have been proposed to
extend the half-life of siRNA (3,15,20).
Delivery of siRNA or shRNA can also be achieved
by using viral vectors. Thus far, retroviral, lentiviral and
adenoviral vector systems for RNA delivery have been
developed. Retroviral vectors are based on the murine
stem cell virus or Moloney murine leukaemia virus and
permit a stable introduction of shRNA into dividing
cells. Lentiviral vectors are derived from the human im-
munodeficiency virus (HIV)-1 and can infect both divid-
ing and nondividing postmitotic cells. Adenoviral vec-
tors based on adeno-associated viruses can infect both
dividing and nondividing cells and since they integrate
a site specifically into the AASV1 region of chromosome
19, they are safer than retroviral or lentiviral vectors,
which are associated with insertional mutagenesis (1,21).
The disadvantages of adenoviral vectors are the lack of
tissue tropism and the dose-limiting hepatoxicity (2).
In general, two routes of in vivo siRNA and shRNA
delivery can be distinguished: local (intranasal, intra-
vitreous, intratracheal, intracerebral, intramuscular, in-
tratumoral) or systematic (intravenous, intraperitoneal)
(22). Both RNA types can be delivered to the cell using
either route. The choice of using one or the other means
of delivery depends on the targeted tissues as well as on
the disease. Electroporation and topical gels are tech-
niques commonly used for local siRNA delivery; the for-
mer is most commonly used for administration into
liver and brain. Electroporation has also been used to
deliver siRNA into the kidneys, eyes, muscles and skin
of rodents. In a study done by Akaneya et al. (23) elec-
troporation was performed using two needle electrodes
inserted in vivo into a restricted brain region of a rat. Al-
though this method, like other local delivery methods,
brings a benefit in controlling 'off-target tissue' effects, it
has one major disadvantage: the use of high voltage in
attempting to increase uptake efficiency.
Topical gels, as a means of siRNA delivery to cells,
could open the way for dermatological applications, as
well as the treatment of cervical cancer (1,24).
The first systemic delivery of siRNA in vivo was car-
ried out using the hydrodynamic technique of inserting
naked siRNA in a large volume of physiological solution
under high pressure into the tail vein of mice (18,25). A
number of different approaches have been developed
for the in vivo delivery of siRNA, all with the same aim:
to improve cellular uptake and site-specific delivery.
Compared to local delivery methods, systemic de-
livery has the same purpose, to reach specific disease
tissues, and to overcome other problems, such as poten-
tial serum degradation.
Thus far, atelocollagen has been shown to be the
best harmless biomaterial for in vivo siRNA delivery.
Atelocollagen is obtained from type I collagen of calf
dermis by pepsin treatment. At the N- and C-terminals
of collagen molecules there is an amino acid sequence
called telopeptide; it contains most of collagen antigen-
icity. Atelocollagen obtained by pepsin treatment is low
in immunogenicity because it is telopeptide-free. The
surface of atelocollagen molecules is positively charged;
molecules can therefore bind electrostatically with nega-
tively charged nucleic acid molecules. Furthermore, it is
believed that siRNA complexed with atelocollagen is re-
sistant to nucleases and is transduced efficiently into the
cells, thereby allowing long-term silencing (18). Chitosan
is another material used for siRNA delivery. It is a natu-
rally occurring cationic polysaccharide, biocompatible,
noninflammatory, nontoxic and biodegradable (4). Alter-
natively, polyethylenimine (PEI) is used because of its
ability to form non-covalent interpolyelectrolyte com-
plexes with DNA or RNA. During investigations, siRNAs
complexed with PEI are protected against degradation
in the presence of nucleases but retain full biological ac-
tivity (20). PEI, as a substance foreign to the living cell,
bears a certain level of toxicity and this has to be taken
into consideration (10). In some studies, however, siRNAs
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have been conjugated with derivates of cholesterol,
lithocholic or lauric acid and all these biological sub-
stances seemed to stabilize siRNAs in a way that they
facilitate their binding to human serum albumin and in-
crease their uptake by the liver (26). Also, cell-penetrat-
ing peptides covalently or noncovalently attached to
siRNA molecules have provided an efficient uptake
mechanism of complexes through the process of inter-
nalization, which is somehow different from endocytosis
(27).
Nonspecific Effects of Using RNA Interference
Off-target activity is the main problem of RNAi
technology. This is due to the fact that siRNA can target
more than one mRNA molecule because it can tolerate
several mismatches when pairing. While a single mis-
match between siRNA and its desired target will only
reduce specific silencing efficiency, the same siRNA may
still be able to downregulate the expression of non-tar-
geted genes that contain regions of partial complemen-
tarity. Another important consideration is the case when,
experimentally, a restricted portion of a particular mRNA
is targeted by RNAi; siRNAs corresponding to other
portions of mRNA can be detected as well. This phe-
nomenon is called transitive RNAi and has been ob-
served in C. elegans and in plants. In C. elegans, these
secondary siRNAs are homologous to sequences up-
stream of those targeted by the primary trigger. How-
ever, besides off-target downregulations, upregulations
have also been observed in vitro (4,28).
Possible Use of RNA Interference
One of the most exciting opportunities offered by
RNAi is the ability to identify all the genes required for
certain physiological processes using the genome-wide
RNAi screens. Cancer, as a condition characterized by a
dense network of signal-transducing pathways, is in the
centre of interest in RNAi usage. A major problem is
that oncogenes and oncosuppressors involved in cancer
do not contribute equally to carcinogenesis, making it
difficult to identify the key genes whose blockage would
lead to tumour cell death. RNAi technology is the most
prospective tool that could help uncover the role of
functional genes in cancer development and could also
serve as potential therapeutic strategy because of its
high efficacy and specificity in the down-regulating
gene expression. However, in most cancers, blockage of
a single gene does not suffice to eliminate the disease
and usually multiple pathways are supposed to be in-
hibited simultaneously in order to prevent malignant
proliferation. Target genes most widely investigated by
researchers are receptors associated with certain mito-
genic pathways known to be involved in malignancy.
More relevant examples are the protein tyrosine kinase
(PTK), a member of the receptor tyrosine kinase path-
way, and the adenomatosis polyposis coli (APC) protein,
a member of the Wnt signalling pathway (1,29). Among
other cancer genes, genes that encode multidrug-resis-
tance (MDR) protein, telomerase, and an integral mem-
brane protein named B-cell lymphoma 2 (Bcl-2) protein
are further examples of genes that are not mutated in
cancer but are overexpressed in a variety of cancers and
are representative targets for silencing. Thus far, initial
in vitro studies have demonstrated effective silencing of
a wide variety of mutated oncogenes, such as Kirsten
ras (K-Ras), which encodes proteins with GTP-ase activ-
ity, human epidermal growth factor-like receptor 2
(Her2/neu), and bcr-abl oncogene that causes Philadel-
phia-chromosome-positive (Ph+) leukaemia (1,18,25).
RNAi can also be directed against several genes in-
volved in cell cycle control in order to promote tumour
cell apoptosis by preventing cell division. Major at-
tempts at RNA silencing have also been made on the
retinoblastoma tumour suppressor (RB) and p53 protein.
p53 is a transcription factor considered to be involved in
the control of the cell cycle (cell proliferation, cell divi-
sion, apoptosis). It is mutated in almost one half of can-
cers. Cellular senescence as well as tumour-host interac-
tions are other processes that can be targeted through
RNAi.
Among the most important targets in this area are
the vascular endothelial growth factor (VEGF) and the
VEGF-receptor, which have a major role in angiogenesis
(26). In January 2009, Alnylam Pharmaceuticals received
a clearance from FDA to start the first clinical trial of an
RNAi drug targeted against the gene for kinesin spindle
protein (KSP), the protein essential for tumour spread-
ing, and the previously mentioned gene for VEGF,
which enables tumour growth by helping formation of
blood vessels. This new candidate, called ALN-VSP, has
been designed to treat primary liver tumours; due to its
encapsulation in lipid nanoparticles, it is capable of cir-
culating throughout the body after being administered
via intravenous infusion.
Another example of VEGF targeting is bevasiranib,
a drug molecule already in Phase 3 clinical trials in pa-
tients with age-related macular degeneration (AMD).
AMD is caused by the abnormal growth of blood ves-
sels behind the retina leading to loss of vision (27). In
Phase 1 and 2 clinical trials, bevasiranib, after being ad-
ministered directly into the eye (intravitreal injection),
did not affect the patient systemically, but locally inhib-
ited the overgrowth of blood vessels that would other-
wise lead to vision loss.
Other attractive targets for the RNAi technique are
diseases caused by viruses and bacteria. In the case of
viruses, genes essential for virus replication, for the as-
sembly of viral particles and host genes, and viral genes
important for virus-host interactions are good targets for
siRNAs. These are usually surface antigens responsible
for virus protein recognition and entrance into the cell.
For example, in the case of HIV, virus silencing can be
achieved through the primary HIV receptor chemokine
(C-C motif) receptor 5 (CCR5) by siRNA targeted against
mRNA transcribed from its gene (1,30). In the case of
human papilloma virus (HPV), it is possible to induce
apoptosis of tumour cells in primary patient tumour
samples by targeting the E6 gene of HPV. E6 protein is a
transcriptional activator essential for malignant transfor-
mation as well as maintenance of a malignant tumour
phenotype. Thus, when silenced with anti-E6 siRNA,
the future development of a tumour cell is prevented
(31,32). Many other animal viruses, especially respira-
tory viruses, are considered to be targets for RNAi ther-
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apy. This is because epithelial cells of the respiratory
tract have been proven to be good uptakers of siRNA
even without transfection, which would enable an easy
way of their administration through inhalation (31,33),
though some delivery problems concerning lung surfac-
tants remain to be solved (34). In contrast to viruses,
bacteria are not generally subject to silencing by siRNA
because they mainly replicate outside the host cell and
lack the necessary machinery. However, it might be pos-
sible to reduce life-threatening bacterial infections which
lead to adverse consequences by silencing the host
genes involved in those aspects of the immune response
or by silencing the host genes involved in mediating
bacterial invasion (1).
RNAi could also be used for studies of different im-
munological diseases. Possible targets in this field are
molecules expressed on the surface of immune cells
(CDs, cytokine and chemokine receptors, adhesion mol-
ecules), cytokines and chemokines, and intracellular sig-
nal transducing proteins. Examples also include trans-
forming growth factor beta (TGF-b) and the nuclear
transcription factor kappa B (NF-kB) (2,3).
Conclusions
RNAi-based gene therapy has great potentials in the
treatment of cancer and infectious diseases, as well as
genetic diseases. RNAi has a variety of important func-
tions in plants and animals, such as a defence mecha-
nism to protect the genome from viruses and other for-
eign nucleic acids. The critical issue of using RNAi for
therapeutic purposes is the fact that exogenous manipu-
lation could undesirably interfere with the function of
endogenous RNAi – antiviral protection. Efficiency of
the therapeutic use of RNAi in cancer relies on the de-
velopment of safe and efficacious delivery systems that
introduce siRNA and shRNA expression vectors into tar-
get tumour cells without disturbing cell homeostasis.
The RNAi approach will hopefully replace the more
toxic traditional treatment modalities and lead to better
tolerated but more effective anticancer therapeutics. In
general, the efficiency of the therapeutic use of RNAi re-
lies on the conditions such as lack of toxicity, specificity
of silencing effects and efficacy of silencing in vitro and
in vivo.
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